AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 33631774
Drug: Once-weekly prophylaxis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-weekly prophylaxis with nonacog alfa 100 IU/kg (12 months)
Trial: 33631774
Drug: On-demand nonacog
RxNorm normalized name: nonacog alfa
DrugBank: Coagulation Factor IX (Recombinant) (DB00100)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: On-demand nonacog alfa (6 months; dose at investigator's discretion)
Trial: 33631774
Drug: Once-weekly prophylaxis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-weekly prophylaxis with nonacog alfa
Trial: 33632155
Drug: CAR-T cell
RxNorm normalized name: SynKIR-meso CAR-T cells
DrugBank: SynKIR-110 (DB17365)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CAR-T cell infusion
Trial: 33632171
Drug: Male participants
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Male participants with SARS-CoV-2 antibodies
Trial: 33632171
Drug: Female participants
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Female participants with SARS-CoV-2 antibodies
Trial: 33632262
Drug: BCI-FES hand
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BCI-FES hand therapy system
Trial: 33632707
Drug: Hyperinsulinemia measures
RxNorm normalized name: MEASLES VIRUS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperinsulinemia measures (insulin, HOMA-IR, HOMA-%β)
Trial: 33632755
Drug: Digital health
RxNorm normalized name: MENS HEALTH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Digital health solutions
Trial: 33632874
Drug: NLG207 (Formerly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NLG207 (Formerly CRLX101) in combination with Enzalutamide
Trial: 33633114
Drug: Lentivirus-mediated gene
RxNorm normalized name: Immature cell growth-inhibiting gene 1 protein
DrugBank: Cerliponase alfa (DB13173)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Lentivirus-mediated gene therapy
Trial: 33633977
Drug: One-stage direct-to-implant
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One-stage direct-to-implant technique using acellular dermal matrix (ADM)
Trial: 33633977
Drug: Two-stage expander-to-implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two-stage expander-to-implant technique
Trial: 33634616
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group 2 (no gel)
Trial: 33634616
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group 1 (excipient-based gel)
Trial: 33635141
Drug: Ibudilast 100
RxNorm normalized name: ibudilast
DrugBank: Ibudilast (DB05266)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Ibudilast 100 mg/day
Trial: 33636454
Drug: Inhaled Azacitidine
RxNorm normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Inhaled Azacitidine (15, 30, and 45 mg/m daily on days 1-5 and 15-19 of 28-day cycles)
Trial: 33636454
Drug: Inhaled Azacitidine
RxNorm normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Inhaled Azacitidine (higher doses)
Trial: 33636454
Drug: Inhaled Azacitidine
RxNorm normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Inhaled Azacitidine (pre- and post-treatment bronchoscopy)
Trial: 38839252
Drug: Metformin use
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin use
Trial: 33637087
Drug: Metformin initiation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin initiation
Trial: 33638035
Drug: PIM447 250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PIM447 250 mg QD
Trial: 33638035
Drug: PIM447 300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PIM447 300 mg QD
Trial: 33638113
Drug: AKCEA-TTR-L
RxNorm normalized name: AKCEA-TTR-LRx
DrugBank: Eplontersen (DB16199)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AKCEA-TTR-L
Trial: 33638263
Drug: Antidepressant medication
RxNorm normalized name: ANTIDEPRESSANTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antidepressant medication (escitalopram or duloxetine) for 8 weeks
Trial: 33638863
Drug: abaloparatide-sMTS 300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: abaloparatide-sMTS 300 μg once daily for 29 days
Trial: 33639190
Drug: DVH (best
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DVH (best cut-off: V46Gy ≥80 cc)
Trial: 33639190
Drug: Constrained bowel
RxNorm normalized name: Constrained Metal (Curcuma Longa)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Constrained bowel loops (V46 < 80 cc)
Trial: 33639518
Drug: Progressive muscle
RxNorm normalized name: ActivOn Joint & Muscle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Progressive muscle relaxation training with music therapy (2 sessions per week for 3 months)
Trial: 33639900
Drug: Umbilical cord
RxNorm normalized name: Sus Scrofa Umbilical Cord
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Umbilical cord mesenchymal stem cells (UC-MSCs) injected intravenously at a dose of 1 × 10^6 cells/kg
Trial: 33639900
Drug: Standard immunosuppressive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard immunosuppressive therapy (IST)
Trial: 33639987
Drug: Midkine inhibition
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midkine inhibition via adeno-associated virus (AAV) targeting; specific dosage and duration not mentioned.
Trial: 33639987
Drug: Midkine levels
RxNorm normalized name: peanut allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midkine levels in plasma and lung; specific dosage and duration not mentioned.
Trial: 33639987
Drug: In vitro
RxNorm normalized name: glucuronidase in vitro test
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In vitro study using inhibitors targeting candidate receptors of midkine; specific dosage and duration not mentioned.
Trial: 33639990
Drug: Miransertib treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Miransertib treatment for a median duration of 22 months (range 22-28).
Trial: 33640028
Drug: Facilitators identified
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Facilitators identified include 'recognizing and addressing' by close others, 'waiting times and availability', 'recommendations and referrals' by health care professionals, and 'positive role models for treatment'.
Trial: 33640346
Drug: His-optimized cardiac
RxNorm normalized name: Leonurus cardiaca extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: His-optimized cardiac resynchronization therapy (HOT-CRT)
Trial: 33640521
Drug: Patient-centered opioid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient-centered opioid prescription guidelines
Trial: 33640521
Drug: Nonopioid analgesics
RxNorm normalized name: Analgesic Balm GRX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonopioid analgesics
Trial: 33640521
Drug: Prescribed pills
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prescribed pills
Trial: 33640578
Drug: Pre-treatment FDG-PET
RxNorm normalized name: Pet-ema
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre-treatment FDG-PET and DWI-MR imaging parameters
Trial: 33640871
Drug: Ribociclib 300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ribociclib 300 mg three weeks in a row with a 1 week break and everolimus 2.5 mg daily (first 12 patients)
Trial: 33640871
Drug: Ribociclib 200
RxNorm normalized name: ribociclib 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ribociclib 200 mg and everolimus 2.5 mg daily (additional 9 patients)
Trial: 33640871
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of ribociclib and everolimus
Trial: 33641211
Drug: Ixazomib (MLN9708)
DrugBank: Ixazomib (DB09570)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ixazomib (MLN9708) 4 mg in combination with Fulvestrant
Trial: 33641374
Drug: 3-Month Dual
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 3-Month Dual Antiplatelet Therapy
Trial: 33641385
Drug: Endovascular therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endovascular therapy (EVT) performed in 49 patients (32.7%; mechanical thrombectomy, n=43)
Trial: 33643689
Drug: Radiotherapy (RT)
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Radiotherapy (RT) 6 or 8 Gy x 2 or 3 doses followed by 4 cycles of ipilimumab
Trial: 33643905
Drug: Aromatase inhibitor
RxNorm normalized name: Aromatase inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aromatase inhibitor (AI) monotherapy
Trial: 33644235
Drug: Neutralizing antibody
RxNorm normalized name: Neutralizing antibody
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neutralizing antibody quantification using ELISA and luminescent SARS-CoV-2 pseudotype
Trial: 33646302
Drug: HLA-haploidentical HSCT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HLA-haploidentical HSCT with age-adapted myeloablative conditioning and T-cell immunotherapy
Trial: 33647009
Drug: C-reactive protein
RxNorm normalized name: C-reactive protein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: C-reactive protein (CRP) at ≥20mg/L
Trial: 33647009
Drug: Procalcitonin (PCT)
RxNorm normalized name: Procalcitonin
DrugBank: Procalcitonin (DB14812)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Procalcitonin (PCT) at 0.5 ng/ml
Trial: 33647548
Drug: Sequential irinotecan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential irinotecan (Arm A)
Trial: 33647913
Drug: Renal Autologous
RxNorm normalized name: Sus scrofa renal pelvis preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Renal Autologous Cell Therapy (REACT); 2 doses at 6-month intervals
Trial: 33648577
Drug: 4% chlorhexidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4% chlorhexidine gluconate solution
Trial: 33650179
Drug: Weekly carfilzomib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly carfilzomib (20/70 mg/m²), cyclophosphamide, and dexamethasone (wKCd)
Trial: 33650972
Drug: Internet-delivered cognitive
RxNorm normalized name: DELIVER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internet-delivered cognitive behavior therapy
Trial: 33651116
Drug: Intravenous administration
RxNorm normalized name: intravenous administration set
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous administration of 37 MBq (± 10%)
Trial: 33651243
Drug: Remifentanil infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil infusion with conversation
Trial: 33651243
Drug: Remifentanil infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil infusion in a quiet environment
Trial: 33653216
Drug: Induction with
RxNorm normalized name: Marcaine with Epinephrine Injectable Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction with fludarabine, cyclophosphamide, and ofatumumab; consolidation with 4 doses of ofatumumab for MRD+ patients
Trial: 33653216
Drug: Overall treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall treatment (including induction and consolidation)
Trial: 33653294
Drug: Standard practice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard practice treatment according to the center
Trial: 33653374
Drug: CPS-mandated treatment
RxNorm normalized name: methylcellulose (1500 CPS)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CPS-mandated treatment
Trial: 33654090
Drug: BBV152 vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BBV152 vaccine candidate (three different formulations) administered at 0 and 14 days
Trial: 33655971
Drug: Interlaminar epidural
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interlaminar epidural steroid injection (ILESI)
Trial: 33656739
Drug: Peficitinib 50
RxNorm normalized name: peficitinib
DrugBank: Peficitinib (DB11708)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Peficitinib 50 or 100 mg/day (with dose adjustments allowed)
Trial: 33657594
Drug: Antibiotic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic treatment following French guidelines, specifically amoxicillin.
Trial: 33658052
Drug: Arsenic trioxide
RxNorm normalized name: Arsenic Trioxide
DrugBank: Arsenic trioxide (DB01169)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Arsenic trioxide (ATO) 0.10 mg/kg, 0.15 mg/kg, and 0.20 mg/kg IV infusions
Trial: 33659204
Drug: Apatinib 425
RxNorm normalized name: Apatinib
DrugBank: Rivoceranib (DB14765)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apatinib 425 mg once daily
Trial: 33659261
Drug: Guided therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guided therapy
Trial: 33660194
Drug: LY3023414 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LY3023414 200 mg BID
Trial: 33661190
Drug: Ibrutinib, 840
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibrutinib, 840 mg PO QD
Trial: 33662447
Drug: Risk-stratified treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risk-stratified treatments based on disease biomarkers
Trial: 33663941
Drug: Neratinib at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neratinib at 240 mg daily in 28-day cycles
Trial: 33664128
Drug: hu3S193, 30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hu3S193, 30 mg/m² intravenous infusions
Trial: 33669715
Drug: Music-based rhythmic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Music-based rhythmic auditory stimulation (RAS) in combination with conventional physiotherapy
Trial: 33671555
Drug: IO103 vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IO103 vaccine with Montanide adjuvant
Trial: 33671691
Drug: Probiotic product
RxNorm normalized name: Rezyst Probiotic Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic product (1 capsule/day)
Trial: 33673868
Drug: Wearable patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wearable patch for remote monitoring of vital signs (heart rate, respiratory rate, temperature) during stay in hotel quarantine.
Trial: 33674856
Drug: Facebook group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Facebook group intervention to reduce barriers to evidence-based smoking cessation treatment
Trial: 33675179
Drug: Telisotuzumab vedotin
RxNorm normalized name: Telisotuzumab vedotin
DrugBank: Telisotuzumab vedotin (DB15104)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telisotuzumab vedotin 2.4 mg/kg
Trial: 33675179
Drug: Telisotuzumab vedotin
RxNorm normalized name: Telisotuzumab vedotin
DrugBank: Telisotuzumab vedotin (DB15104)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telisotuzumab vedotin 2.7 mg/kg
Trial: 33675179
Drug: Telisotuzumab vedotin
RxNorm normalized name: Telisotuzumab vedotin
DrugBank: Telisotuzumab vedotin (DB15104)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telisotuzumab vedotin (both doses)
Trial: 33675184
Drug: High-dose chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose chemotherapy (HDCT) with TI-CE regimen, including two cycles of paclitaxel and ifosfamide followed by three cycles of HD carboplatin plus etoposide, with carboplatin dose adapted based on clearance to reach a target AUC of 24 mg.min/mL per cycle.
Trial: 33675184
Drug: High-dose chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose chemotherapy (HDCT) with TI-CE regimen.
Trial: 33675184
Drug: High-dose chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose chemotherapy (HDCT) with TI-CE regimen for high- and very high-risk patients.
Trial: 33676628
Drug: Pirtobrutinib 200
RxNorm normalized name: PIRTOBRUTINIB 200MG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pirtobrutinib 200 mg daily
Trial: 33677480
Drug: Nivolumab plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nivolumab plus ipilimumab (anti-PD-1 and anti-CTLA-4) combination therapy
Trial: 33677504
Drug: Increased mineralocorticoid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Increased mineralocorticoid dose during childhood
Trial: 33677553
Drug: Chemical renal
RxNorm normalized name: nirmatrelvir
DrugBank: Nirmatrelvir (DB16691)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Chemical renal denervation (RDN) using Peregrine System Infusion Catheter, Ablative Solutions (n = 4; 2F:2M)
Trial: 33677615
Drug: UGN-101 (mitomycin-containing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UGN-101 (mitomycin-containing reverse thermal gel)
Trial: 33679478
Drug: Internet-Administered Emotional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internet-Administered Emotional Awareness and Expression Therapy
Trial: 33681244
Drug: Improved use
RxNorm normalized name: Improvest
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Improved use of chewing gum during capsule endoscopy
Trial: 33681273
Drug: Long-term treatments
RxNorm normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Long-term treatments (three different types)
Trial: 33681747
Drug: Melatonin (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melatonin (20 mg nightly for one year)
Trial: 33682447
Drug: Belantamab mafodotin
RxNorm normalized name: belantamab mafodotin
DrugBank: Belantamab mafodotin (DB15719)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Belantamab mafodotin combined with novel agents (GSK3174998, feladilimab, nirogacestat, dostarlimab)
Trial: 33682447
Drug: Belantamab mafodotin
RxNorm normalized name: belantamab mafodotin
DrugBank: Belantamab mafodotin (DB15719)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Belantamab mafodotin monotherapy
Trial: 33682527
Drug: Opioid receptor
RxNorm normalized name: Opioid receptor agonist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Opioid receptor antagonists, specific dosage and duration not mentioned
Trial: 39647797
Drug: Anakinra 100
RxNorm normalized name: ANAKINRA 100MG INJ,SYRINGE,1ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anakinra 100 mg subcutaneously once daily for 10 days
Trial: 37364223
Drug: nab-paclitaxel monotherapy
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: nab-paclitaxel monotherapy
Trial: 33683582
Drug: Escitalopram monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Escitalopram monotherapy (n = 82, ESC-CONT)
Trial: 33683582
Drug: Adjunctive Aripiprazole
RxNorm normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Adjunctive Aripiprazole (n = 88, ESC-ARI)
Trial: 33683917
Drug: Umbralisib 800
RxNorm normalized name: Umbralisib
DrugBank: Umbralisib (DB14989)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Umbralisib 800 mg orally once daily until disease progression, unacceptable toxicity, or study withdrawal
Trial: 33683917
Drug: Umbralisib 800
RxNorm normalized name: Umbralisib
DrugBank: Umbralisib (DB14989)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Umbralisib 800 mg orally once daily
Trial: 33684160
Drug: GSK1070806 (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK1070806 (3 mg/kg intravenous)
Trial: 33684377
Drug: Subcutaneous immunoglobulin
RxNorm normalized name: immunoglobulin A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous immunoglobulin (SCIG) at 0.1 g/kg/week for up to 6 months
Trial: 33685522
Drug: MANTRa therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MANTRa therapy (24 to 34 individual weekly sessions)
Trial: 33685522
Drug: TAU (treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAU (treatment as usual, weekly sessions)
Trial: 33685522
Drug: MANTRa therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MANTRa therapy
Trial: 33686413
Drug: Individualised luteal
RxNorm normalized name: Nuphar lutea leaf extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individualised luteal phase support (iLPS) through daily subcutaneous P4 injections (Psc) started the day prior to FET.
Trial: 33686452
Drug: Crenigacestat (LY3039478)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Crenigacestat (LY3039478) in combination with LY3023414
Trial: 33686452
Drug: Crenigacestat (LY3039478)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Crenigacestat (LY3039478) in combination with abemaciclib
Trial: 33686452
Drug: Crenigacestat (LY3039478)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Crenigacestat (LY3039478) in combination with taladegib
Trial: 33686631
Drug: Talazoparib (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Talazoparib (1 mg/day for mild renal impairment, 0.75 mg/day for moderate renal impairment, 0.5 mg/day for severe renal impairment)
Trial: 33686631
Drug: Talazoparib (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Talazoparib (0.5 mg/day for severe renal impairment)
Trial: 33687163
Drug: Metformin (1500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin (1500 mg per day)
Trial: 34261767
Drug: Non-surgical periodontal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-surgical periodontal treatment (NSPT)
Trial: 33687667
Drug: Automated method
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Automated method based on shape analysis using Gaussian support vector machine (G-SVM) for ECoG electrodes recognition.
Trial: 33687667
Drug: Automated method
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Automated method based on shape analysis using Gaussian support vector machine (G-SVM) for simultaneous recognition of depth and ECoG electrodes.